Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Cogent Biosciences (COGT) Stock Price & Analysis
513 Followers
COGT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.67 - $13.50
Previous Close$7.53
Volume846.31K
Average Volume (3M)2.14M
Market Cap
$719.97M
Enterprise Value$460.10M
Total Cash (Recent Filing)$279.04M
Total Debt (Recent Filing)$19.17M
Price to Earnings (P/E)-3.1
Beta0.03
Next Earnings
May 07, 2024EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding103,913,396
10 Day Avg. Volume1,412,082
30 Day Avg. Volume2,137,282
Standard Deviation0.67
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)3.96
Price to Sales (P/S)397.39
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue233.67
Enterprise Value/Gross Profit175.54
Enterprise Value/Ebitda-3.28
Forecast
1Y Price Target
$15.44Price Target Upside105.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Cogent Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressCogent Biosciences has shown promising clinical progress with bezuclastinib demonstrating activity and safety, potentially outperforming competitor Ayvakit and indicating strong potential efficacy for the treatment of systemic mastocytosis.
Drug Approval And Commercial SuccessDeciphera's oncology asset Qinlock is FDA approved and recommended in the NCCN guidelines for certain cancer patients, leading to a significant increase in its market potential.
Financial HealthThe company reported substantial cash and cash equivalents, providing a robust financial position and a cash runway into 2027, ensuring the company's operational stability and continued investment in research and development.
Bears Say
Clinical Trials And EfficacyNo clear dose response, with the lower dose outperforming the higher dose on multiple endpoints.
Market CompetitionDespite bezuclastinib's promising efficacy and safety, there is ongoing debate about its clinical relevance and impact on the market, particularly due to Ayvakit's significant first mover advantage.
Regulatory ChallengesCogent does not have sign-off from the FDA on MS2D2, and they expect to meet with the FDA to discuss.
---
Ownership Overview
24.42% Insiders
13.77% Mutual Funds
19.68% Other Institutional Investors
42.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.67 and its highest was $13.50 in the past 12 months.
What is Cogent Biosciences’s market cap?
Currently, no data Available
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is May 07, 2024 which is tomorrow.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Feb 26, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.554 by -$0.076.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -$0.51.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 95,613,396 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.554. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Among the largest hedge funds holding Cogent Biosciences’s share is Fairmount Funds Management Llc. It holds Cogent Biosciences’s shares valued at 21M.
---
Cogent Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.44 (105.05% Upside)
$15.44 (105.05% Upside)
Hedge Fund Trend
Decreased
By 8.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.83%
12-Months-Change
Fundamentals
Return on Equity
-74.94%
Trailing 12-Months
Asset Growth
4.20%
Trailing 12-Months
Company Description
Cogent Biosciences
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
---
COGT Stock 12 Months Forecast
Average Price Target
$15.44
▲(105.05% Upside)
Technical Analysis
Best Analysts Covering COGT
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-8.91%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -8.91% per trade.
---